3,582 results match your criteria: "Amsterdam Rheumatology & Immunology Center[Affiliation]"
Rheumatology (Oxford)
January 2025
Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
Objectives: To explore thresholds for the Psoriatic Arthritis (PsA) Impact of Disease questionnaire (PsAID12) score against disease activity measures in an observational setting, in patients with PsA.
Methods: The baseline data from the ReFlaP observational, prospective, multicentre and international study was used (NCT03119805). Cutoffs for PsAID12 were determined against disease activity scores, defining disease impact states (ie remission, low impact, moderate impact and high impact).
Nat Commun
January 2025
Centre for translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Protective immunity to malaria depends on acquisition of parasite-specific antibodies, with Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) being one of the most important target antigens. The effector functions of PfEMP1-specific IgG include inhibition of infected erythrocyte (IE) sequestration and opsonization of IEs for cell-mediated destruction. IgG glycosylation modulates antibody functionality, with increased affinity to FcγRIIIa for IgG lacking fucose in the Fc region (Fc-afucosylation).
View Article and Find Full Text PDFFront Immunol
January 2025
Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Introduction: Upon infection, T cell-driven B cell responses in GC reactions induce memory B cells and antibody-secreting cells that secrete protective antibodies. How formation of specifically long-lived plasma cells is regulated via the interplay between specific B and CD4+ T cells is not well understood. Generally, antibody levels decline over time after clearance of the primary infection.
View Article and Find Full Text PDFRMD Open
December 2024
Rheumatology, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands
Objectives: To assess the effect of treatment on haemostatic parameters in patients with early rheumatoid arthritis (RA).
Methods: Patients with newly diagnosed RA started methotrexate and were randomised to additional conventional treatment, certolizumab pegol, abatacept or tocilizumab. Several biomarkers for haemostasis were analysed including parameters of the two global haemostatic assays-overall haemostatic potential (OHP) and endogenous thrombin potential (ETP), as well as single haemostatic factors-fibrinogen, prothrombin fragment 1+2 (F1+2), D-dimer, thrombin activatable fibrinolysis inhibitor (TAFI) and clot lysis time (CLT) in 24 patients at baseline, 12 and 24 weeks after the start of the treatment.
Joint Bone Spine
December 2024
Rheumatology Department, Cochin Hospital, APHP.centre, Paris, France; INSERM U-1153, Center for Research in Epidemiology and Statistic Université Paris Cité, Paris, France.
J Allergy Clin Immunol Pract
December 2024
Servicio de Alergia, Hospital Clínico San Carlos, IdISSC, Madrid, Spain; Facultad de Medicina, Universidad Complutense, Madrid, Spain. Electronic address:
Background: Fish allergy affects children and adults worldwide and there are transient and persistent phenotypes.
Objective: We aimed to analyze persistence, severity and reactivity thresholds in challenge-confirmed fish allergic patients sensitized to parvalbumin.
Methods: Patients 12-65 years-old reporting immediate reactions to fish, with fish skin prick test ≥5 mm and IgE to cod and carp β-parvalbumins ≥0.
Eur J Nucl Med Mol Imaging
December 2024
Department of Nuclear Medicine & Molecular Imaging (EB50), University Medical Center Groningen, University of Groningen, Hanzeplein 1, PO, 9700 RB, Groningen, The Netherlands.
Rheumatology (Oxford)
December 2024
Department of Rheumatology, Erasmus MC, Rotterdam, The Netherlands.
Objectives: To evaluate the short and long term effects of an online, interactive, multifactorial lifestyle intervention program (Leef! Met Reuma) on health risk and all ICHOM-recommended patient reported outcome measures(PROMs) in patients with an Inflammatory Arthritis(IA), OsteoArthritis(OA) or FibroMyalgia(FM).
Methods: Patients with an IA, OA or FM, could register for the lifestyle intervention program. The program consists of a 3-month intensive part followed by a 21-month aftercare period and focuses on 4 pillars, namely nutrition, exercise, relaxation and sleep.
Clin Rheumatol
December 2024
Immunology and Histocompatibility Department, Hedi Chaker University Hospital, Sfax, Tunisia.
Introduction/objectives: Psoriatic arthritis (PsA) is a chronic inflammatory rheumatism belonging to the spondyloarthritis family. It is a multifactorial disease whose genetic determinism is still poorly understood. It is favored by environmental factors in genetically predisposed individuals.
View Article and Find Full Text PDFLancet Microbe
December 2024
Leiden University Center for Infectious Diseases Leiden University Medical Centre, Leiden, Netherlands. Electronic address:
Background: SARS-CoV-2 has been associated with a higher proportion of asymptomatic infections and lower mortality in sub-Saharan Africa than high-income countries. However, there is currently a lack of data on cellular immune responses to SARS-CoV-2 in people living in Africa compared with people in high-income regions of the world. We aimed to assess geographical variation in peripheral and mucosal immune responses.
View Article and Find Full Text PDFEur J Immunol
December 2024
Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Arthritis Res Ther
December 2024
Department of Rheumatology and Clinical Immunology, Amsterdam UMC, Meibergdreef 9, Room G7-126, Amsterdam, 1105 AZ, the Netherlands.
Background: This study aimed to assess the quantitative uptake of F-FDG PET-CT in the lungs of patients with early severe diffuse cutaneous systemic sclerosis (SSc) with and without interstitial lung disease (ILD), compared to controls. In patients with SSc-ILD, F-FDG uptake was correlated to high-resolution computed tomography (HRCT) and pulmonary function test (PFT) parameters.
Methods: A prospective, cross-sectional study was conducted, involving 15 patients with SSc-ILD, 5 patients with SSc without ILD, and 7 controls without SSc.
Adv Rheumatol
December 2024
Amsterdam Rheumatology and Immunology Center, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Objectives: Describe tofacitinib safety from an integrated analysis of randomized controlled trials (RCTs) in patients with ankylosing spondylitis (AS).
Method: Pooled data from Phase 2 (NCT01786668; 04/2013-03/2015)/Phase 3 (NCT03502616; 06/2018-08/2020) RCTs in AS patients were analyzed (3 overlapping cohorts): 16-week placebo-controlled (tofacitinib 5 mg twice daily [BID] [n = 185]; placebo [n = 187]); 48-week only-tofacitinib 5 mg BID (n = 316); 48-week all-tofacitinib (≥ 1 dose of tofacitinib 2, 5, or 10 mg BID; n = 420). Baseline 10-year atherosclerotic cardiovascular disease (ASCVD) risk was determined in patients without history of ASCVD (48-week cohorts).
Clin Gastroenterol Hepatol
December 2024
Sanquin Research, and Landsteiner Laboratory, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam institute for Immunology and Infectious Diseases, Immunology, Amsterdam, The Netherlands; Sanquin Diagnostic Services, Amsterdam, The Netherlands.
Arthritis Rheumatol
December 2024
Department of Preventive Dentistry, Academic Center for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Clin Gastroenterol Hepatol
December 2024
Gastroenterology and Digestive Endoscopy, IRCCS Ospedale San Raffaele.
Background And Aim: Our aim was to evaluate outcomes of maintenance treatments for EoE among observational studies (OSs) and randomized controlled trials (RCTs).
Materials And Methods: Studies reporting histological success of maintenance therapy ≥ 48 weeks were included. Primary outcome was histological success rate (defined as <15/<6 eos/HPF).
RMD Open
December 2024
Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Objectives: To compare the construct validity, including discrimination between known groups, of three pain and three morning stiffness (MS) measurement instruments.
Methods: Patients with radiographic axial spondyloarthritis with 8-year data from the Outcome in Ankylosing Spondylitis International Study cohort were assessed cross-sectionally. Three instruments for pain and three for MS, all self-reported and scored 0-10, were compared.
RMD Open
December 2024
Rheumatology & Clinical Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
Secondary lymphoid organs such as lymph nodes (LNs) are the home of peripheral tolerance mechanisms which control autoreactive T cells and prevent immune responses to self-antigen. In systemic autoimmunity, there is a clear failure of these peripheral tolerance mechanisms that leads to chronic inflammation and tissue destruction, highlighting the role for LNs as possible gatekeepers of autoimmunity. In recent years there has been a shift in research focus towards tissue sites in autoimmune diseases ranging from type 1 diabetes to rheumatoid arthritis in an effort to better characterise pathogenesis and guide diagnostic and therapeutic decisions.
View Article and Find Full Text PDFArthritis Care Res (Hoboken)
December 2024
Leiden University Medical Center, Leiden, the Netherlands.
Objective: We aimed to characterize hand osteoarthritis (OA) patients with deteriorating or improving hand pain, and to investigate patients achieving good clinical outcome after four years.
Methods: We used four year annual Australian/Canadian hand osteoarthritis index (AUSCAN) pain subscale (range 0-20) measurements from the HOSTAS cohort (hand OA patients). Pain changes were categorized as deterioration, stable and improvement using the Minimal Clinical Important Improvement (MCII).
Crit Care
December 2024
Julius Center for Health Sciences and Primary Care, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
Background: Low endogenous immunoglobulin(Ig)-levels are common in critically ill patients with sepsis, but it is unknown whether low Ig-levels are associated with poor outcome, and in which patients Ig-replacement therapy (IgRT) improves outcome. Given the crucial role of immunoglobulins in eliminating certain encapsulated pathogens, we examined the relationship between serial Ig-levels and disease course in critically ill patients with community acquired pneumonia (sCAP) caused by encapsulated or other pathogens.
Methods: We included a cohort of consecutive critically ill patients with CAP, and PaO/FiO-ratio < 200 with or without septic shock, from an existing biorepository where microbiological causes of infection had been adjudicated in a protocolized manner.
Cochrane Database Syst Rev
December 2024
Centre for Health, Exercise and Sports Medicine, The University of Melbourne, Victoria, Australia.
Ther Adv Musculoskelet Dis
November 2024
Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, Amsterdam, The Netherlands.
Background: The efficacy and safety of bimekizumab (BKZ), an inhibitor of interleukin (IL)-17F in addition to IL-17A, has been established in axial spondyloarthritis (axSpA). Early assessment of new bone formation is possible using F-fluoride positron emission tomography-computerised tomography (PET-CT) imaging to quantitatively monitor osteoblastic activity.
Objectives: This exploratory study, initiated before phase IIb/III studies, assessed the efficacy and safety of BKZ in patients with radiographic (r-)axSpA and its effect on new bone formation.
Rheumatol Adv Pract
November 2024
Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark.
Ann Rheum Dis
November 2024
Center for Bone Quality, Leiden University Medical Center, Leiden, The Netherlands.
Background: There is considerable practice variation in labelling, diagnosis and treatment of adults with sterile bone inflammation. We developed a expert consensus recommendations on the disease definition, diagnosis and treatment of this rare condition.
Methods: Systematic literature review and Grading of Recommendations, Assessment, Development and Evaluations-based appraisal of evidence, two Delphi surveys and three digital and in-person consensus meetings with a multidisciplinary expert panel and patient representatives.
Eur Burn J
July 2024
Department of Clinical Psychology, Utrecht University, 3584 CS Utrecht, The Netherlands.
Burn care quality indicators are used to monitor and improve quality of care and for benchmark purposes. The perspectives of burn survivors, however, are not included in current sets of quality indicators while patient-centred care gains importance. The aim of this study was to explore burn survivors' perspectives on quality aspects of burn care, which was used to translate their perspectives into patient-centred quality of care indicators.
View Article and Find Full Text PDF